{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:10:29Z","timestamp":1788988229659,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.neurot.2026.e00930","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T09:03:10Z","timestamp":1779872590000},"page":"e00930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety profile and potential clinical risks of xanomeline and trospium chloride: A real-world pharmacovigilance study using FAERS"],"prefix":"10.1016","volume":"23","author":[{"given":"Zhuocheng","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10323","key":"10.1016\/j.neurot.2026.e00930_bib1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia","volume":"399","author":"Jauhar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2026.e00930_bib2","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019","volume":"28","author":"Solmi","year":"2023","journal-title":"Mol Psychiatr"},{"issue":"18","key":"10.1016\/j.neurot.2026.e00930_bib3","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia","volume":"381","author":"Marder","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00930_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the global Burden of Disease Study 2019","volume":"9","author":"Collaborators","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00930_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorthoj","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00930_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyaf015","article-title":"From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1\/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials","volume":"28","author":"Meyer","year":"2025","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.neurot.2026.e00930_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1359786810385490","article-title":"Suicide and schizophrenia: a systematic review of rates and risk factors","volume":"24","author":"Hor","year":"2010","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00930_bib8","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and management of treatment-resistant schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00930_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.neurot.2026.e00930_bib10","article-title":"Cognitive dysfunction in schizophrenia: an expert group paper on the current state of the art","volume":"29","author":"Harvey","year":"2022","journal-title":"Schizophr Res Cogn"},{"key":"10.1016\/j.neurot.2026.e00930_bib11","article-title":"The relationship between cognition and functioning in schizophrenia: a semi-systematic review","volume":"27","author":"Kharawala","year":"2022","journal-title":"Schizophr Res Cogn"},{"issue":"10202","key":"10.1016\/j.neurot.2026.e00930_bib12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00930_bib13","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00930_bib14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2147\/NDT.S455279","article-title":"New therapeutic targets and drugs for schizophrenia beyond dopamine D2 receptor antagonists","volume":"20","author":"Peng","year":"2024","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.neurot.2026.e00930_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fncel.2013.00055","article-title":"Cholinergic connectivity: it's implications for psychiatric disorders","volume":"7","author":"Scarr","year":"2013","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.neurot.2026.e00930_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.heares.2020.108003","article-title":"Mechanisms of GABAergic and cholinergic neurotransmission in auditory thalamus: impact of aging","volume":"402","author":"Richardson","year":"2021","journal-title":"Hear Res"},{"key":"10.1016\/j.neurot.2026.e00930_bib17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1749-6632.1999.tb11332.x","article-title":"Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons","volume":"868","author":"Radcliffe","year":"1999","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00930_bib18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3565(25)38667-2","article-title":"Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors","volume":"269","author":"Shannon","year":"1994","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00930_bib19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","article-title":"Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia","volume":"179","author":"Paul","year":"2022","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00930_bib20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","article-title":"Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists","volume":"9","author":"Mirza","year":"2003","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.neurot.2026.e00930_bib21","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00213-023-06362-2","article-title":"Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results","volume":"240","author":"Breier","year":"2023","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00930_bib22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N Engl J Med"},{"issue":"10422","key":"10.1016\/j.neurot.2026.e00930_bib23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2026.e00930_bib24","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00930_bib25","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/d41573-024-00155-8","article-title":"FDA approves first schizophrenia drug with new mechanism of action since 1950s","volume":"23","author":"Kingwell","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurot.2026.e00930_bib26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamapsychiatry.2021.3990","article-title":"Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials","volume":"79","author":"Taipale","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00930_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2026.e00930_bib28","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00930_bib29","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA Adverse Event Reporting System (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS","volume":"118","author":"Potter","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00930_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00474","article-title":"Risk of angioedema and thrombolytic therapy among stroke patients: an analysis of data from the FDA adverse event reporting system database","volume":"22","author":"Xiang","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00930_bib31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.neurot.2026.e00930_bib32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jad.2025.04.091","article-title":"A systematic analysis of safety profile of Brexanolone in real-world use based on FAERS database","volume":"382","author":"Jiang","year":"2025","journal-title":"J Affect Disord"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00930_bib33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.neurot.2026.e00930_bib34","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.neurot.2026.e00930_bib35","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","article-title":"Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA adverse event reporting system","volume":"19","author":"Cecco","year":"2024","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.neurot.2026.e00930_bib36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2165\/11599740-000000000-00000","article-title":"A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data","volume":"35","author":"Cornelius","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.neurot.2026.e00930_bib37","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.ekir.2024.07.006","article-title":"Exploring novel adverse events of nefecon","volume":"9","author":"Wang","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00930_bib38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11154-011-9184-2","article-title":"Sex steroids and schizophrenia","volume":"13","author":"Markham","year":"2012","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.neurot.2026.e00930_bib39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/archpsyc.60.6.565","article-title":"Sex differences in the risk of schizophrenia: evidence from meta-analysis","volume":"60","author":"Aleman","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00930_bib40","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24m15497","article-title":"Safety and tolerability of Xanomeline and Trospium chloride in Schizophrenia: pooled results from the 5-Week, randomized, double-blind, placebo-controlled EMERGENT trials","volume":"86","author":"Kaul","year":"2025","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00930_bib42","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/sj.bjp.0704781","article-title":"M(3) muscarinic receptors mediate contraction of human urinary bladder","volume":"136","author":"Fetscher","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.neurot.2026.e00930_bib43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/00002018-200831050-00002","article-title":"Drug-induced urinary retention: incidence, management and prevention","volume":"31","author":"Verhamme","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.neurot.2026.e00930_bib44","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00003088-200544070-00003","article-title":"Clinical pharmacokinetics of trospium chloride","volume":"44","author":"Doroshyenko","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00930_bib45","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/bjd.15808","article-title":"Neural control of sweat secretion: a review","volume":"178","author":"Hu","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.neurot.2026.e00930_bib46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev-pharmtox-051921-023858","article-title":"Targeting the actions of muscarinic receptors on dopamine systems: new strategies for treating neuropsychiatric disorders","volume":"64","author":"Nunes","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00930_bib47","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/mds.23050","article-title":"Motor behavior abnormalities in drug-naive patients with schizophrenia spectrum disorders","volume":"25","author":"Peralta","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurot.2026.e00930_bib48","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jsmc.2010.08.003","article-title":"Neuropharmacology of sleep and wakefulness","volume":"5","author":"Watson","year":"2010","journal-title":"Sleep Med Clin"},{"key":"10.1016\/j.neurot.2026.e00930_bib49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0024-3205(98)00578-5","article-title":"Development of muscarinic receptors and regulation of secretory responsiveness in rodent sweat glands","volume":"64","author":"Landis","year":"1999","journal-title":"Life Sci"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00930_bib50","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.13374","article-title":"Systemic review: the pathogenesis and pharmacological treatment of hiccups","volume":"42","author":"Steger","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00930_bib51","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1176\/appi.ajp.20241186","article-title":"Long-term safety and efficacy of Xanomeline and Trospium chloride in schizophrenia: a 52-Week open-label extension trial","volume":"183","author":"Kaul","year":"2026","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00930_bib52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.31887\/DCNS.2018.20.1\/bpenninx","article-title":"Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications","volume":"20","author":"Penninx","year":"2018","journal-title":"Dialogues Clin Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00930_bib53","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.encep.2012.03.002","article-title":"[Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance]","volume":"40","author":"Besnard","year":"2014","journal-title":"Encephale"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00930_bib54","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14740338.2024.2392002","article-title":"An Updated Safety Review of the Relationship Between Atypical Antipsychotic Drugs, the QTc Interval and Torsades de Pointe As: implications for Clinical Use","volume":"23","author":"Melo","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.neurot.2026.e00930_bib55","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/schbul\/sbr081","article-title":"A disappearing heritage: the clinical core of schizophrenia","volume":"37","author":"Parnas","year":"2011","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.neurot.2026.e00930_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1192\/bjp.187.1.9","article-title":"Schizophrenia and suicide: systematic review of risk factors","volume":"187","author":"Hawton","year":"2005","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00930_bib57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1146\/annurev.pharmtox.44.101802.121453","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"44","author":"Gandhi","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.neurot.2026.e00930_bib58","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.neurot.2026.e00930_bib59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/wps.21155","article-title":"Sex differences need to be considered when treating women with psychotropic drugs","volume":"23","author":"Sommer","year":"2024","journal-title":"World Psychiatry"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00930_bib60","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1176\/ajp.149.5.587","article-title":"Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication","volume":"149","author":"Yonkers","year":"1992","journal-title":"Am J Psychiatry"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00930_bib61","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American geriatrics society 2023 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults","volume":"71","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"Suppl 21","key":"10.1016\/j.neurot.2026.e00930_bib62","first-page":"11","article-title":"Anticholinergic effects of medication in elderly patients","volume":"62","author":"Tune","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00930_bib63","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41537-022-00320-1","article-title":"Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophrenia"},{"key":"10.1016\/j.neurot.2026.e00930_bib64","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jclinepi.2021.01.015","article-title":"Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases","volume":"134","author":"Khouri","year":"2021","journal-title":"J Clin Epidemiol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:39:11Z","timestamp":1788986351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926001005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1878747926001005"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00930","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profile and potential clinical risks of xanomeline and trospium chloride: A real-world pharmacovigilance study using FAERS","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00930"}}